GLP-1 drugs linked to lower addiction rates in large study of veterans: The treatments appeared to help prevent a wide range of substance use disorders and reduce serious harms from existing ones.

The article focuses on emerging evidence that glucagon-like peptide-1 (GLP-1) receptor agonists, drugs commonly prescribed for diabetes and obesity, may reduce the risk and severity of substance use disorders (SUDs). A large study of U.S. veterans found that those treated with GLP-1 analogs were less likely to develop new SUDs and experienced fewer overdoses, hospitalizations, and deaths related to substance use compared to those on other diabetes medications. While some clinicians are prescribing GLP-1 drugs off-label for addiction, experts emphasize that more randomized controlled trials are needed before these drugs can be recommended over existing FDA-approved treatments. Researchers suggest that if proven effective, GLP-1 analogs could broaden access to addiction treatment and help reduce stigma by repurposing a medication already widely accepted for diabetes. [Extracted from the article]